Andrew Mazar

Andrew Mazar has a diverse work experience in the biotech and pharmaceutical industries. Andrew served as the Chief Operating Officer at Actuate Therapeutics, Inc. since 2015, where they contributed to the development of the drug elraglusib for the treatment of advanced cancer. Andrew also held the role of Co-founder and Principle Scientific Adviser at Actuate Therapeutics from January 2015 to July 2022. Additionally, Andrew Mazar worked as part of the Scientific Advisory Board at SEngine Precision Medicine starting in January 2023.

Before Actuate Therapeutics, Andrew Mazar co-founded Lung Therapeutics, Inc. in 2013, a clinical stage drug development company focused on lung fibrosis. Andrew also founded Tactic Pharma LLC in 2010, where they served as the managing member and Chief Scientific Officer.

Andrew Mazar was also involved in the founding and development of Monopar Therapeutics, Inc., a clinical stage oncology drug development company, where they held various executive roles including Co-founder, Director, Chief Scientific Officer, and Executive VP of R&D from November 2015 to April 2022.

In addition to their industry experience, Andrew Mazar has academic affiliations. Andrew worked as an Adjunct Professor of Pharmacology at the Feinberg School of Medicine, Northwestern University from September 2016 to April 2019. Prior to that, they held positions at Northwestern University as an Entrepreneur-in-Residence, Research Professor, and Director of the Center for Developmental Therapeutics from June 2009 to August 2016.

Before their positions at Actuate Therapeutics and Lung Therapeutics, Andrew Mazar served as the Chief Scientific Officer at Attenuon, LLC from February 2000 to April 2009. Andrew also worked as a Development Consultant at Wilson Therapeutics from 2012 to 2015.

Andrew Mazar holds a Doctor of Philosophy (Ph.D.) degree in Biochemistry from the University of Illinois College of Medicine. The exact timeframe of their education is not specified.